Using practice effects for targeted trials or sub-group analysis in Alzheimer\u27s disease: How practice effects predict change over time by Wang, Guoqiao et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
1-1-2020 
Using practice effects for targeted trials or sub-group analysis in 
Alzheimer's disease: How practice effects predict change over 
time 
Guoqiao Wang 
Richard E. Kennedy 
Terry E. Goldberg 
Mackenzie E. Fowler 
Gary R. Cutter 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Guoqiao Wang, Richard E. Kennedy, Terry E. Goldberg, Mackenzie E. Fowler, Gary R. Cutter, and Lon S. 
Schneider 
RESEARCH ARTICLE
Using practice effects for targeted trials or
sub-group analysis in Alzheimer’s disease:
How practice effects predict change over time
Guoqiao WangID1, Richard E. Kennedy2, Terry E. Goldberg3, Mackenzie E. FowlerID4, Gary
R. Cutter5, Lon S. Schneider6*
1 Division of Biostatistics, Washington University in St. Louis, St. Louis, Missouri, United States of America,
2 Comprehensive Center of Aging Health, University of Alabama at Birmingham, Birmingham, Alabama,
United States of America, 3 Department of Psychiatry, Columbia University, New York, New York, United
States of America, 4 Department of Epidemiology, University of Alabama at Birmingham, Birmingham,
Alabama, United States of America, 5 Department of Biostatistics, University of Alabama at Birmingham,
Birmingham, Alabama, United States of America, 6 Department of Psychiatry and The Behavioral Sciences,




To describe the presence of practice effects in persons with Alzheimer disease (AD) or mild
cognitive impairment (MCI) and to evaluate how practice effects affect cognitive progression
and the outcome of clinical trials.
Methods
Using data from a meta-database consisting of 18 studies including participants from the
Alzheimer disease Cooperative Study (ADCS) and the Alzheimer Disease Neuroimaging
Initiative (ADNI) with ADAS-Cog11 as the primary outcome, we defined practice effects
based on the improvement in the first two ADAS-Cog11 scores and then estimated the pres-
ence of practice effects and compared the cognitive progression between participants with
and without practice effects. The robustness of practice effects was investigated using CDR
SB, an outcome independent the definition itself. Furthermore, we evaluated how practice
effects can affect sample size estimation.
Results
The overall percent of practice effects for AD participants was 39.0% and 53.3% for MCI
participants. For AD studies, the mean change from baseline to 2 years was 12.8 points for
the non-practice effects group vs 7.4 for the practice effects group; whereas for MCI studies,
it was 4.1 for non-practice effects group vs 0.2 for the practice effects group. AD participants
without practice effects progressed 0.9 points faster than those with practice effects over a
period of 2 years in CDR-SB; whereas for MCI participants, the difference is 0.7 points. The
sample sizes can be different by over 35% when estimated based on participants with/with-
out practice effects.
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Conclusion
Practice effects were prevalent and robust in persons with AD or MCI and affected the cog-
nitive progression and sample size estimation. Planning of future AD or MCI clinical trials
should account for practice effects to avoid underpower or considers target trials or stratifi-
cation analysis based on practice effects.
Introduction
Despite the increase in sample size and duration of Alzheimer’s disease (AD) clinical trials in
efforts to detect small clinical effects, recent phase 3 trials failed to detect effective treatments
[1–4]. In order to reduce sample sizes and improve efficacy for AD trials, targeted trials or sub-
group selection trials which select participants based on genotype (e.g. APOE), cognitive status
(e.g. Mini-Mental State Examination (MMSE)), and/or AD biomarkers (e.g. CSF Aβ and tau,
or amyloid PET), have been recommended [5–7]. But targeted trials or sub-group selection
based on genotype APOE ε4 or cognitive status were shown to possibly be inefficient through
simulation using pooled AD trial data [8, 9]. Similarly, two recent phase 3 targeted trials of
bapineuzumab selected 1331 AD participants who were not APOE ε4 carriers and 1121 who
were APOE ε4 carriers based on the hypothesis that non-carriers were responsive to bapineuzu-
mab, whereas carriers were not, did not achieve the expected reduction in AD assessment scale-
cognitive subscale (ADAS-Cog11). Thus either the treatment is ineffective or this is consistent
with the conclusion that designing targeted trial or sub-group selection based on genotype
APOE ε4 may not work unless there was a sufficiently large differential treatment effect
between the APOE ε4 groups [8, 9]. These targeted trials or sub-group selection rely on assump-
tions that certain genotypes and biomarkers predict more rapid change in ADAS-Cog11 or
other clinical outcomes, making it easier to see differences in treatment effects. These assump-
tions are made, however, despite the uncertainty of how well established the relationship is, and
the fact that the biomarkers have often diverged from hypothesized cognitive results [10].
Adding to these shortcomings is the imperfect measurement of cognitive functions. One
prevalent issue is most cognitive tests have learning curves or practice effects [11]. Thus, it
may be worthwhile to consider the presence or absence of practice effects as a classifier in clini-
cal trials. Practice effects are defined as the improvement in serial cognitive tests with the same
or similar test materials [12]. Practice effects can be identified in subjects with mild cognitive
impairment (MCI) or AD, and improvement in serial cognitive tests due to practice effects
can lead to an effect size (ratio of change in test-retest scores to its standard error) in low to
medium effect size range [13].
Several findings have emerged to support using practice effects as a classifier in clinical
trials. For example, short-term practice effects are correlated to AD biomarkers such as amyloid
deposition and brain hypometabolism [12, 14]. Practice effects may distinguish cognitively
intact elders from those with MCI in that the former demonstrate larger practice effects
whereas the latter may or may not [15]. In a study focusing on amnestic MCI, practice effects
were shown to predict cognitive outcome after one year [16]. However, these findings were
based on small samples and thus needed validation in larger cohorts [12, 14–16]. Furthermore,
it is unknown how practice effects affect the change in serial cognitive tests (such as the rate of
change and its variability) in longitudinal studies, and how it could be utilized in AD clinical
trials. We aim to investigate the applicability of using practice effects as a classifier for designing
targeted MCI or AD clinical trials or sub-group analyses using a meta-database of 18 studies.
Practice effects for targeted trials or sub-group analysis
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Method
Data sources
Subjects were from a meta-database consisting of 18 studies including participants from the
Alzheimer’s Disease Cooperative Study (ADCS) and the Alzheimer’s Disease Neuroimaging
Initiative (ADNI), representing both clinical trials and observational studies in AD, MCI, and
normal individuals [17]. Of these 18 studies, 10 which had ADAS-cog scores with follow-up
duration over 12 months could be used for this study (9 AD studies and 1 MCI study). After
exclusion of those with missing values at baseline/screening, or at the first visit after baseline/
screening, or at both, a total of 2499 AD participants and 1191 MCI participants were included
in this study. In doing so, practice effects were defined for the same time interval within each
study. All data obtained from the Alzheimer’s Disease Cooperative Study were deidentified
and anonymized before access.
Outcomes
The 11-item ADAS-Cog was the primary outcome measure for most of these trials and used in
all of the trials. It is a brief cognitive battery that evaluates memory, reasoning, orientation,
praxis, language, and word finding difficulty and is scored as a composite from 0 to 70 errors
with higher scores indicating worse impairment [18]. The clinical dementia rating-sum of
boxes (CDR-SB) was the secondary outcome, which evaluates memory, orientation, judgment
and problem solving, community affairs, home and hobbies, and personal care. Each item or
domain is scored 0, 0.5, 1, 2, or 3 in increasing severity (the personal care item does not allow a
0.5 score). It too is scored as a composite rating, the six domains summed to a score from 0 to
18 with higher score indicating worse impairment [19].
Definition of practice effects
Hassenstab et al. defined practice effect using the slope of the first three yearly measurements
[20]. As they and others observed, practice effects occur mostly between the first and second
administration of the test [20–23]. Thus, we defined practice effects based on the first two mea-
surements. This method was chosen also due to its easy implementation in a real clinical trial
setting, where simple and non-model-based methods are preferred to avoid any selection bias.
A participant was considered demonstrating practice effects if this individual’s first ADAS--
Cog11 score (at screening or at baseline) is higher than or equal to the second, meaning
improvement or lack of worsening in cognitive scores is observed. To avoid defining false
practice effects due to random measurement error, we conducted sensitivity analysis where
the practice effects was defined as a minimum of 2 points improvement in ADAS-Cog11 from
the first to the second assessment.
Robustness of practice effects
The practice effects were defined using ADAS-Cog11, to evaluate the robustness of practice
effects, we chose a secondary outcome CDR-SB. CDR-SB offered multiple advantages to test
the robustness. First, it was independent of the definition of practice effects which was based
on ADAS-Cog11 although it is not completely immune to practice effects. Second, very few
items in CDR-SB are overtly susceptible to practice effects and the ratings themselves are sub-
jective, making any differences observed in CDR-SB between the practice effects groups most
likely to be true differences rather than due to regression to the mean or random errors. Third,
almost every study with ADAS-Cog11 also had CDR-SB, minimizing the impact of sample size
difference between these two outcomes.
Practice effects for targeted trials or sub-group analysis
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Statistical analysis
We characterized the study cohort using descriptive statistics and calculated the prevalence of
practice effects for each trial. Baseline ADAS-Cog11, age, and the years of education were com-
pared using ANOVA. The association between practice effects and age, sex, education, and
baseline ADAS-Cog11 was investigated using multiple variable logistic regressions for pooled
AD participants and pooled MCI participants, respectively.
The mixed model for repeated measure (MMRM) with time as a categorical variable was
used for the primary analyses in three different ways. (i) It was applied to each clinical trial,
separately, to estimate the mean over time and compare the change from baseline in ADAS--
Cog11 between the practice effects group and the non-practice effects group. (ii) Then the indi-
vidual ADAS-Cog11 scores of the same visits in the 10 AD studies were pooled together for
another MMRM analysis for AD participants and MCI participants, respectively. Specifically,
the scores at baseline, 6 months, 12 months, 18 months, and 24 months were pooled. (iii)
Finally, MMRM was applied in the same way as in (ii) with CDR-SB as the dependent variable.
The MMRM model was constructed with group effect (practice effects group vs non-practice
effects group), time effect, and group by time interaction as the fixed effects with an unstruc-
tured covariance matrix.
Sample size estimation were conducted for subjects with and without practice effects based
on pooled AD studies and MCI studies, respectively. Similar to previous trials [1, 3], we first
estimated the mean (SD) of the 2-year change from baseline, then under the assumption of
equal variance among the treatment groups, we estimate the sample size for a given treatment
effect using two-sample t-tests and equal randomization ratio. The treatment effect is either an
absolute reduction or a percentage reduction in the mean change from baseline.
Analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
Results
Practice effects and ADAS-Cog11 progression over time
Participants with practice effects were observed in all 10 studies (ADNI AD and ADNI MCI
were considered as 1 study) ranging from 26.9% to 57.7% (Table 1). The overall percent of
practice effects for AD participants was 39.0% and 53.3% for MCI participants. The percent
of practice effects is 42.1% in pooled treatment arm and is 44.2% in the pooled placebo arm
(p = 0.19). Participants with and without practice effects had similar number of years of educa-
tion in all 10 studies, and significantly differed in age in 3 studies (Table 1). Significantly higher
mean baseline ADAS-Cog11 levels were found for participants with practice effects in 6 studies
(again ADNI AD and ADNI MCI were considered as 1 study) (Table 1). For AD participants,
practice effects were only associated with baseline ADAS-Cog11; for a 1 point increase in base-
line ADAS-cog, the odds of demonstrating practice effect increased by 1.6% (odds ratio: 1.016
[95% CI: 1.008–1.023]). For MCI participants, practice effects were associated with baseline
ADAS-Cog11 and age. For a 1 point increase in baseline ADAS-Cog11, the odds of demonstrat-
ing practice effects increased by 10.2% (odds ratio: 1.102 [95% CI: 1.070–1.135]); whereas for 1
year increase in age, the odds of demonstrating practice effect decreased by 4% (odds ratio:
0.960 [95% CI: 0.944–0.977]).
The estimated mean ADAS-Cog11 score for patients with practice effects was generally
higher at baseline than for those without practice effects at baseline, but lower in post baseline
visits in all but one study regardless of the similarity in the mean baseline ADAS-Cog11 (S1
and S2 Figs). Generally, the mean post-baseline trajectories over time demonstrated a parallel
pattern (S1 and S2 Figs). When estimating the change from baseline, the non-practice effects
Practice effects for targeted trials or sub-group analysis
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group in the AD studies worsened 5.3 to 10.7 points by 1.5 years and 8.9 to 17.5 points by 2
years; whereas the practice effects group worsened 3.0 to 10.2 points by 1.5 years and 5.5 to
12.5 points by 2 years (S3 and S4 Figs). In the MCI studies, the non-practice effects group
worsened 3.1 to 4.1 points by 1.5 years and 5.8 to 7.1 points by 3 years; whereas the practice
effects group improved by 0.1 to 0.3 points by 1.5 years and worsened 2.4 to 3.0 points by 3
years.
After pooling the data, similar results were observed for the mean ADAS-Cog11 over time
(Fig 1). For pooled AD studies, the mean change from baseline to 2 years was 12.8 points for
the non-practice effects group vs 7.4 for the practice effects group; whereas for MCI studies, it
was 4.1 for non-practice effects group vs 0.2 for the practice effects group (S5 Fig).
Practice effects affect change in CDR-SB
With the same practice effects groups defined by ADAS-Cog11 scores, we investigated the pro-
gression using an alternative outcome, the CDR-SB, pooling data for AD and for MCI, respec-
tively. This would avoid potential problems with defining practice effects based on the same
instrument used for the trial outcome. The practice effects group had slightly lower mean
CDR-SB than the non-practice effects group at baseline, but the discrepancy increased from
0.1 at baseline to 1.0 over a period of 2 years with faster progression in the latter (p = 0.0015
for the interaction between practice effects group and time) (Fig 2). Similar but smaller dis-
crepancy was also observed for pooled MCI studies, and the discrepancy increased from 0.1 to







N (%) with Practice Effects Baseline ADAS-cog11 Baseline Age, y Education, y
Treatment Placebo p N/
Total, (%)
PE�� Non-PE p PE�� Non-PE p PE�� Non-PE p
ADNI
AD




20.0 17.9 0.0439 76.5 74.5 0.0991 14.7 14.8 0.92






23.5 23.7 0.8051 75.5 76.0 0.6102 14.5 14.2 0.3810






24.2 23.6 0.7029 75.0 75.4 0.7118 12.4 12.2 0.7419






23.8 21.4 0.0074 76.5 76.3 0.7426 14.0 13.8 0.5173






25.5 23.1 0.0235 74.6 73.8 0.4183 14.0 14.4 0.2177






22.9 23.9 0.3715 74.5 73.5 0.2501 14.2 13.9 0.3756






24.1 19.9 0.0121 70.6 73.8 0.0134 14.2 13.9 0.6091






38.3 38.9 0.5907 72.8 72.2 0.5360 12.6 12.4 0.7548






31.2 27.4 0.0036 75.4 75.7 0.8011 13.3 13.9 0.2012
ADNI
MCI




12.5 10.8 0.0003 73.9 75.6 0.0241 15.5 15.8 0.45






11.9 10.2 <.0001 72.0 73.2 0.0240 14.7 14.7 0.996
Baseline ADAS-cog scores for participants with practice effects were significantly higher than for those without in 6 trials but were similar in the other 4 trials. Age and
the years of education were mostly similar.
PE: practice effects, Non-PE: Non-practice effects
https://doi.org/10.1371/journal.pone.0228064.t001
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0.8 over a period of 36 months with faster progression observed in the non-practice effects
group (p = 0.0001 for the interaction between practice effects group and time) (Fig 2).
Practice effects affect sample sizes
When planning AD clinical trials, the sample size can be estimated in two ways. One is to esti-
mate the mean (SD) of the change from baseline to the end of study for the primary endpoint
using pilot studies or previously published studies; then a minimum clinical meaningful differ-
ence (or mean clinically important difference) is chosen to calculate the sample size. For exam-
ple, in the EXPEDITION and EXPEDITION2 trials, the minimum clinical meaningful
difference was chosen to be 1.8 points at 18 months on the ADAS-Cog11 [1] in patients with
mild to moderate AD; whereas subsequently in the EXPEDITION3 trial, the minimum clinical
meaningful difference was chosen to be 1.5 points at 18 months using the expanded ADAS--
Cog14 [3], and in a mild AD subset. Because the practice effects group has smaller variance
than the non-practice effects group, it has smaller sample size when the same minimum clini-
cal meaningful difference is used for both groups (Fig 3, left panel). With all things being equal
(e.g. 80% power, 5% type I error, two-sided test, equal duration), the sample size for the
Fig 1. Estimated mean ADAS-Cog11 over time for pooled AD/MCI studies. Similar results to those individual studies were observed
for the mean ADAS-Cog11 over time.
https://doi.org/10.1371/journal.pone.0228064.g001
Fig 2. CDR-SB progression over time for pooled AD studies and pooled MCI studies. For both AD and MCI studies, the non-
practice effects group progressed faster.
https://doi.org/10.1371/journal.pone.0228064.g002
Practice effects for targeted trials or sub-group analysis
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practice effects cohort is 46% of that for the non-practice effects cohort. Another common way
to consider sample size is to assume that the treatment effect leads to a certain percentage
reduction for the treatment group compared with the progression of the placebo group. Based
on the pooled AD studies, the mean (SD) decline in 2 years is 7.4 (6.74) for the practice effects
group and 12.8 (9.91) for the non-practice effects group. A 10% reduction will lead to an abso-
lute reduction of 0.74 and 1.28 for the practice and non-practice effects groups, respectively.
The sample sizes estimated from this perspective are shown in the right panel of Fig 3. When
all things being equal, the sample size for the practice effects cohort is 138% of that for the
non-practice effects cohort.
Sensitivity analysis using new practice effects group
Using the redefined practice effects groups (improvement of at least 2 points in ADAS-Cog11),
we re-ran all the analysis and obtained similar results in terms of the progression in CDR-SB,
the change over time in ADAS-Cog11, and the variance of each group. Because some practice
effects subjects under the first definition now belonged to the non-practice effects group under
the second definition, the difference between the two groups for the second definition became
smaller (S6 and S7 Figs).
Discussion
Using a meta-database with over 3000 participants, we demonstrated that those with practice
effects showed substantially less worsening on the ADAS-Cog11 over the course of 3 to 24
months than those without. The difference in the rate of change in ADAS-Cog11 between those
with practice effects and those without is even larger than the difference expected between
experimental drugs and placebo in current trials or from the observed effects of marketed cho-
linesterase inhibitors compared with placebo. The 3- to 5-point difference across 18 months of
trial duration is 2 to 3 times the differences planned in the current clinical trials of experimental
drugs for mild or moderate dementia due to AD for early AD trials [1, 3, 4, 24], or the actual
difference in marketed cholinesterase inhibitors trials compared with placebo [25, 26].
Varying the mixture of participants with practice effects and those without in AD trials,
therefore, may have significant impact on the outcome of such trials due to the large
Fig 3. Sample size comparison for different sample size estimation methods (based on 80% power, 5% type I error, two-sided test,
equal duration). The left panel estimated the sample size by assuming the same minimum clinical meaningful difference; whereas the
right panel by assuming the same percentage reduction in the progression of the placebo group. Sample size were estimated based on
two-sample t-tests.
https://doi.org/10.1371/journal.pone.0228064.g003
Practice effects for targeted trials or sub-group analysis
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differences in sample sizes. For example, assuming that the percentage reduction is the same,
the change in ADAS-Cog11 in the practice effects group is 2 points and in the non-practice
effects group is 4 points with a common SD 8, then a 40% reduction would lead to an effect
size of 0.1 (= 2�40%/8) for the practice effects group and an effect size of 0.2 (= 4�40%/8) for
the non-practice effects group. Given the same sample size, such differences in the change
from baseline and in the resulting effect sizes may be crucial in determining the success of AD
trials. On the other hand, if the same minimum clinical meaningful difference is used for each
group (meaning different percentage reductions are assumed for each group), then the practice
effects group requires a much smaller sample size than the non-practice effects group. How-
ever, it is unclear which group of participants is more likely to respond to an experimental
drug. For example, if the non-practice effects participants are associated with more rapidly
progressive disease that is treatment-resistant, while the practice effects participants are more
slowly progressive but treatment-responsive, then a larger trial with practice effects partici-
pants would be required to detect treatment effects. Moreover, absolute cutoff scores in
ADAS-Cog11 change have been recommended to interpret treatment effects. For example, 1.5-
to 4-point differences in ADAS-Cog11 (11 items or 14 items) over 6 to 18 months have been
considered by some to be minimally clinically relevant [1, 3, 27–29]. Differences in the change
of ADAS-Cog11 from baseline between the practice effects and non-practice effects partici-
pants suggest that these cutoff scores may miss a number of practice effects participants show-
ing a significant change that is less than these thresholds.
Instead of relying on presumed relationships between genotypes or biomarkers and the
ADAS-Cog11 which itself will vary by illness stage, using practice effects provides a direct way
for designing targeted trials or sub-group analyses based on the ADAS-Cog11 sample distribu-
tion for clinical trials. It also offers an alternative standard to measure disease severity based on
the trial participants’ learning ability. Participants who learn or improve their ADAS-Cog11
scores are more likely to be less cognitively impaired than the non-practice effects participants,
even within a narrowly defined study sample. The difference in practice effects can subse-
quently be taken into account in the statistical analysis or used for stratification of subjects to
enhance an efficacy signal [10]. Furthermore, instead of trying to eliminate or alleviate the
impact of practice effects through various strategies [13], using practice effects to design tar-
geted trials or sub-group analyses provides an alternative to take advantage of practice effects
for better signal detection. We cannot, however, make a conclusive recommendation regard-
ing who should be included in targeted trials (non-practice effects subjects vs practice effects
subjects) since no data or published research so far have shown which group is more respon-
sive to the active treatments although a study has shown subjects with practice effects benefit-
ted more from a cognitive intervention [30].
There is a prevalent opinion in AD research community that participants should be treated
in clinical trials during the earlier stages of the illness in order to maximize the treatment bene-
fits. Consequently, sub-group analyses based on the stages of illness have been conducted (e.g.
mild AD vs moderate AD) [1]. The MMSE at visit 1 was commonly used to differentiate mild
AD (e.g. MMSE score of 20 to 26 or 21 to 26) from moderate AD (e.g. MMSE score of 16 to
19), though the thresholds may vary [1, 2, 31]. Given the correlation between ADAS-Cog11
and MMSE and the similarity in their primary cognitive functions [32], the observed practice
effects in ADAS-Cog11 implicate the potential inaccuracy of categorizing disease stages by a
single measurements. In future studies, it may be helpful to use the average of the first two
measurements for categorizing disease stages.
In our analyses, we observed that the strongest predictor of the practice effects group was
the severity of cognitive impairment on the ADAS-Cog11. This tells us that the information
that is classifying individuals as having practice effects may be due to regression toward the
Practice effects for targeted trials or sub-group analysis
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mean [33]. Although this does not imply that those unable to mount practice effects are not
declining faster or reaching critical values sooner. To attempt to assess if the non-practice
effects are truly farther down the cognitive decline scale versus appearing in the group because
of regression toward the mean, we examined a more broadly based, summary clinical out-
come, the CDR-SB, that in addition to assessing memory, orientation, judgment and problem-
solving, requires an assessment of a patient’s participation in community affairs, home and
hobbies, and personal care. Although regression toward the mean could still occur, we expect
this effect would be attenuated on a clinical outcome rating, we could examine if the group
with a more rapid decline posited as those who truly cannot learn could be seen once this
attenuated regression toward the mean were used. In these analyses, we found a group by time
interaction. This suggests that the practice effects are present within the cohort as we defined
them and are not completely due to regression toward the mean. To evaluate the effects of
misclassification of practice effects due to measurement errors in ADAS-Cog11, we re-
classified practice effects groups using a minimum clinical meaningful threshold of 2 points.
Results based on this classification are very similar and reinforce the robustness of practice
effects.
Potential limitations to this study include that the practice effects were defined based on
two assessments collected over a variety of time intervals ranging from 28 weeks to 6 months.
Although it would be ideal if all the intervals were the same, the consistent findings from each
individual study and from the pooled studies alleviated the effects of unequal intervals. In a
planned clinical trial, these two assessments can be collected at the screening and at the base-
line; or consecutively at the baseline with a few hours/days apart before the administration of
experimental drugs. How the results from this study may apply to these scenarios warrant fur-
ther validation. Second, our findings are based on ADAS-Cog11 and need to be tested with dif-
ferent cognitive outcomes. Additionally, using ADAS-Cog11 may underestimate the practice
effect due to its lack of sensitivity to detect changes in preclinical AD stage. The use of mea-
surements with greater sensitivity to change would be expected to lead to even greater power
to detect changes in cognition and function over time. Third, from a pragmatic perspective of
conducting a clinical trial, we employed the most straightforward method to define the prac-
tice effects by using the first two assessments. Although other methods such as the complex
standardized regression-based method can be used [34], these methods involve the use of
demographic variables and may cause selection bias. Finally, the practice effects can be altered
by different cognitive domains, demographic variables, subject variables, retest interval, etc.,
our analyses did not address these issues.
Although, these findings might be confirmed in other pooled databases of cohort studies or
clinical trials, it appears that practice effects can independently reflect participants’ true cogni-
tive status and lead to significant difference in cognitive decline between participants with and
without practice effects. Trial planning without considering practice effects may result in inef-
ficient trials with insufficient power. It may be worthwhile to utilize practice effects in clinical
trials by beginning with planning sub-group analysis in future studies or even targeted trials.
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